{"entity":{"id":"paper-lian-adjuvant-temozolomide-cisplatin-mucosal-melanoma-ccr-2013","kind":"paper","name":"Adjuvant temozolomide plus cisplatin versus high-dose interferon versus observation in resected mucosal melanoma","aka":[],"tldr":"In this Chinese randomised trial, chemotherapy with temozolomide and cisplatin after surgery for mucosal melanoma lengthened relapse-free and overall survival compared with interferon or observation, the only positive adjuvant trial specific to mucosal disease.","summary":"Phase 2 randomised trial of 189 patients with resected mucosal melanoma assigned to observation, high-dose interferon alfa-2b for one year, or six cycles of temozolomide plus cisplatin.\n\nMedian relapse-free survival was 5.4 months with observation, 9.4 months with interferon and 20.8 months with chemotherapy, and median overall survival 21.2, 40.4 and 48.7 months respectively.","asOf":"2026-09-17","links":[{"label":"Clin Cancer Res 2013","url":"https://doi.org/10.1158/1078-0432.CCR-13-0739"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/23833309/"}],"tags":[],"related":[],"cancers":["mucosal-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["cisplatin","temozolomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["clinical-cancer-research"],"dependsOn":[],"notes":[],"journal":"Clinical Cancer Research","year":2013,"doi":"10.1158/1078-0432.CCR-13-0739","pmid":"23833309","authors":"Lian B, Si L, Cui C, et al.","paperType":"rct","findings":["Median relapse-free survival 20.8 months (chemotherapy) vs 9.4 (interferon) vs 5.4 (observation).","Median overall survival 48.7 vs 40.4 vs 21.2 months."],"whatItMeans":"Adjuvant temozolomide-cisplatin is used in China for resected mucosal melanoma; elsewhere anti-PD-1 therapy is extrapolated from cutaneous disease, and the two have since been compared directly.","caveats":["Single-country phase 2 trial in a largely Asian population.","Predates adjuvant immunotherapy."],"changedPractice":true,"participants":189},"route":"/key-papers/paper-lian-adjuvant-temozolomide-cisplatin-mucosal-melanoma-ccr-2013/","neighbours":{"cancer":[{"id":"mucosal-melanoma","kind":"cancer","name":"Mucosal melanoma","route":"/cancers/mucosal-melanoma/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"journal":[{"id":"clinical-cancer-research","kind":"journal","name":"Clinical Cancer Research","route":"/journals/clinical-cancer-research/"}]}}